TrialJapanese journal of clinical oncology2023

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.

Hironaga Satake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.